Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1356 BS in healthy male volunteers
NCT02183311Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2006
- Primary completion
- Oct 2006
01
Overview
Phase 1, randomised, double-blind trial of linagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with abnormal findings in physical examination at 28 days, Number of patients with clinically significant changes in Vital signs at 28 days and 3 more. Started Jun 2006; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183311.